Physician profile
Michael E Adler
NPI 1760643241
$410.19
in general payments reported to CMS, 2019-2025
10 companies · $65.78 in 2025
The $65.78 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.78 · 2022: $63.67 · 2023: $20.63 · 2024: $248 · 2025: $65.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $123.33 | 2024 | |
| Ethicon US, LLC | $31.89 | 2022 | |
| Boston Scientific Corporation | $27.37 | 2025 | General - Biliary Devices |
| Capsovision, INC. | $21.99 | 2025 | Capsocam Plus |
| Glaxosmithkline, LLC. | $20.63 | 2023 | Arexvy, Shingrix |
| Orexo US, INC. | $18.51 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.42 | 2025 | Strensiq |
| Cumberland Pharmaceuticals, INC. | $13.27 | 2022 | |
| Janssen Biotech, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.